Export 24 results:
Author Title [ Type(Desc)] Year
Filters: Author is Blodi, Barbara A  [Clear All Filters]
Journal Article
R. N. Khurana, Oden, N. L., VanVeldhuisen, P. C., Scott, I. U., Blodi, B. A., and Ip, M. S., Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial., Graefes Arch Clin Exp Ophthalmol, vol. 239, no. 7, pp. 1839-1851, 2021.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., King, J., Antoszyk, A. N., Peters, M. A., and Tolentino, M., Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4., JAMA Ophthalmol, vol. 135, no. 6, pp. 639-649, 2017.
I. U. Scott, VanVeldhuisen, P. C., Oden, N. L., Ip, M. S., Blodi, B. A., Hartnett, M. Elizabeth, and Cohen, G., Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10., Ophthalmology, vol. 118, no. 2, pp. 345-52, 2011.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Altaweel, M., and Berinstein, D. M., Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial., JAMA Ophthalmol, vol. 136, no. 4, pp. 337-345, 2018.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Awh, C. C., Kunimoto, D. Y., Marcus, D. M., Wroblewski, J. J., and King, J., Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial., JAMA, vol. 317, no. 20, pp. 2072-2087, 2017.
T. Etheridge, Dobson, E. T. A., Wiedenmann, M., Oden, N., VanVeldhuisen, P., Scott, I. U., Ip, M. S., Eliceiri, K. W., Blodi, B. A., and Domalpally, A., Ellipsoid Zone Defects in Retinal Vein Occlusion Correlates With Visual Acuity Prognosis: SCORE2 Report 14., Transl Vis Sci Technol, vol. 10, no. 3, p. 31, 2021.
A. A. Aref, Scott, I. U., Oden, N. L., Ip, M. S., Blodi, B. A., and VanVeldhuisen, P. C., Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15., JAMA Ophthalmol, vol. 133, no. 9, pp. 1022-9, 2015.
J. S. Peterson, Rockwell, K., Scott, I. U., Ip, M. S., VanVeldhuisen, P. C., and Blodi, B. A., LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS., Retina, vol. 39, no. 9, pp. 1802-1809, 2019.
M. S. Ip, Oden, N. L., Scott, I. U., VanVeldhuisen, P. C., Blodi, B. A., Ghuman, T., and Baker, C. W., Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study., JAMA Ophthalmol, vol. 137, no. 3, pp. 281-287, 2019.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., and Chan, C. K., Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial., JAMA Ophthalmol, 2019.
I. U. Scott, VanVeldhuisen, P. C., Barton, F., Oden, N. L., Ip, M. S., Blodi, B. A., Worrall, M., and Fish, G. E., Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial., JAMA Ophthalmol, 2019.
M. S. Ip, Scott, I. U., VanVeldhuisen, P. C., Oden, N. L., Blodi, B. A., Fisher, M., Singerman, L. J., Tolentino, M., Chan, C. K., and Gonzalez, V. H., A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlus, Arch Ophthalmol, vol. 127, no. 9, pp. 1101-14, 2009.
I. U. Scott, VanVeldhuisen, P. C., Oden, N. L., Ip, M. S., Blodi, B. A., J Jumper, M., and Figueroa, M., SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion., Ophthalmology, vol. 116, no. 3, pp. 504-12, 2009.
C. K. Chan, Ip, M. S., VanVeldhuisen, P. C., Oden, N. L., Scott, I. U., Tolentino, M. J., and Blodi, B. A., SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion., Ophthalmology, vol. 118, no. 7, pp. 1364-72, 2011.
D. V. Weinberg, Wahle, A. E., Ip, M. S., Scott, I. U., VanVeldhuisen, P. C., and Blodi, B. A., Score Study Report 12: Development of venous collaterals in the Score Study., Retina, vol. 33, no. 2, pp. 287-95, 2013.
I. U. Scott, Blodi, B. A., Ip, M. S., VanVeldhuisen, P. C., Oden, N. L., Chan, C. K., and Gonzalez, V., SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type., Ophthalmology, vol. 116, no. 4, pp. 756-61, 2009.
M. S. Ip, Oden, N. L., Scott, I. U., VanVeldhuisen, P. C., Blodi, B. A., Figueroa, M., Antoszyk, A., and Elman, M., SCORE Study report 3: study design and baseline characteristics., Ophthalmology, vol. 116, no. 9, pp. 1770-1777.e1, 2009.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., and Antoszyk, A. N., SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design., Am J Ophthalmol, vol. 148, no. 5, pp. 725-732.e7, 2009.
A. Hendrick, VanVeldhuisen, P. C., Scott, I. U., King, J., Blodi, B. A., Ip, M. S., Khurana, R. N., and Oden, N. L., SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials., Am J Ophthalmol, vol. 222, pp. 185-193, 2020.
I. U. Scott, Figueroa, M. J., Oden, N. L., Ip, M. S., Blodi, B. A., and VanVeldhuisen, P. C., SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion., Am J Ophthalmol, vol. 184, pp. 147-156, 2017.
E. Y. Chew, Clemons, T. E., Sangiovanni, J. Paul, Danis, R. P., Ferris, F. L., Elman, M. J., Antoszyk, A. N., Ruby, A. J., Orth, D., Bressler, S. B., Fish, G. E., Hubbard, G. Baker, Klein, M. L., Chandra, S. R., Blodi, B. A., Domalpally, A., Friberg, T., Wong, W. T., Rosenfeld, P. J., Agrón, E., Toth, C. A., Bernstein, P. S., and Sperduto, R. D., Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3., JAMA Ophthalmol, vol. 132, no. 2, pp. 142-9, 2014.
B. A. Blodi, Domalpally, A., Scott, I. U., Ip, M. S., Oden, N. L., Elledge, J., Warren, K., Altaweel, M. M., Kim, J. E., and Van Veldhuisen, P. C., Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study system for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE Study Report 9., Arch Ophthalmol, vol. 128, no. 9, pp. 1140-5, 2010.
A. Domalpally, Blodi, B. A., Scott, I. U., Ip, M. S., Oden, N. L., Lauer, A. K., and VanVeldhuisen, P. C., The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of optical coherence tomograms: SCORE study report 4., Arch Ophthalmol, vol. 127, no. 11, pp. 1461-7, 2009.